Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
“Flagship Pioneering continues to view the microbiome as a rapidly emerging and highly promising field with vast therapeutic potential. We were pleased to extend our Seres ownership through a new investment fund, as part of the Company’s recent public equity offering. Stephen’s financial and strategic acumen will be valuable assets to the Seres Board,” said
“Seres is a clear leader in the development of microbiome therapeutics, and I am very pleased to join the Company’s Board. I am especially excited to join Seres ahead of the important clinical readouts anticipated in 2020, and the potential to create substantial long-term shareholder value while developing important new medicines,” said Mr. Berenson.
Prior to Flagship, Mr. Berenson spent 33 years in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking, where he focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including Mr. Berenson’s potential contribution to the Company and the timing and results of the Company’s clinical studies.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-Q filed with the
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
Vice President, Investor Relations and Corporate Communications